Document 2985
 DOCN  M94A2985
 TI    Intensive chemotherapy and G-CSF in HIV-associated non-Hodgkin's
       lymphoma.
 DT    9412
 AU    Oksenhendler E; Dubreull ML; Gerard L; Barateau V; Levy Y; Deforges L;
       Ferchal F; Clauvel JP; Hopital Saint-Louis, Paris, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):18 (abstract no. 044B). Unique
       Identifier : AIDSLINE ICA10/94369590
 AB    OBJECTIVE: To evaluate efficacy, safety and virological impact of
       intensive chemotherapy associated with G-CSF in HIV-associated NHL.
       PATIENTS: 33 HIV+ patients with aggressive NHL and CD4+ cells > or =
       100. CDC group IV: 10; mean CD4: 344 (100-910). Burkitt: 16, large cell:
       10, immunoblastic: 4, anaplastic: 3; stage IV: 17; marrow+: 7, CNS+: 9.
       THERAPY: Week 1,3,5: doxorubicin 75 mg/m2 d1, cyclophosphamide 1,2g/m2
       d1, vindesine 2mg/m2 d1&5, bleomycin 10mg d1&5, prednisolone 80mg/m2
       d1to5. W 8,10,12: cyclophosphamide 1g/m2 d1, etoposide 200mg/m2 d1&2,
       methotrexate 3g/m2 d2+folinic acid. G-CSF 5 micrograms/kg d6to13 at each
       cycle. RESULTS: F-up: 14m. Complete remission: 23(70%). Relapse: 2.
       Alive in CR: 19; deaths: 14 (12 with NHL); median survival 13,5m.
       Dose-Intensity: 88% for doxorubicin, 86% for cyclophosphamide. VIROLOGY:
       mean acid-dissociated p24Ag dropped by d6 (-48%, p < .001), remained
       stable with G-CSF and reached baseline value at end of therapy.
       CONCLUSION: LNHIV-91 regimen+G-CSF is effective and safe in selected
       patients with CD4 > or = 100. TABULAR DATA, SEE ABSTRACT VOLUME.
 DE    Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE
       Bleomycins/ADMINISTRATION & DOSAGE  Cyclophosphamide/ADMINISTRATION &
       DOSAGE  Doxorubicin/ADMINISTRATION & DOSAGE  Drug Administration
       Schedule  Etoposide/ADMINISTRATION & DOSAGE  Granulocyte
       Colony-Stimulating Factor/*THERAPEUTIC USE  Human  HIV
       Infections/*COMPLICATIONS  Leucovorin/ADMINISTRATION & DOSAGE  Lymphoma,
       AIDS-Related/DRUG THERAPY/*THERAPY  Lymphoma, Non-Hodgkin's/DRUG
       THERAPY/*THERAPY  Methotrexate/ADMINISTRATION & DOSAGE
       Vindesine/ADMINISTRATION & DOSAGE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).